Barinthus Biotherapeutics (BRNS) Corporate presentation summary

Strategic direction and mission

• Focused on advancing next-generation immunotherapies for autoimmunity and inflammatory diseases using proprietary SNAP-TI technology.

• Aims to restore immune tolerance and reduce inflammation by targeting the underlying causes of immune imbalance.

• Lead candidate VTP-1000 targets celiac disease, with a broader pipeline addressing Type 1 and Type 2 diabetes.

Technology and platform

• SNAP-TI platform enables co-delivery of multiple disease-associated antigens and an immunomodulator via nanoparticles.

• Designed for broad antigen coverage, patient-friendly administration (IM/SC), and improved tolerability.

• Preclinical data show increased Treg/Teff ratio, restoring immune homeostasis and providing antigen-specific immune tolerance.

Clinical development and pipeline

• VTP-1000 is in Phase 1 trials for celiac disease; SAD portion completed with good tolerability and targeted immune response.

• Preclinical and early clinical data indicate VTP-1000 reduces inflammatory cytokines and induces immune tolerance to gluten.

• Pipeline includes CLY-101 (menin inhibitor for T1D/T2D) and CLY-201 (TYK2 inhibitor for T1D), both in early clinical stages.